David Emerson Jorden sold $300k of AURX
CEO/CFO at Nuo Therapeutics, Inc.. 200,000 shares at an average of $1.50, traded Nov 28, 2025, filed Dec 3, 2025.
Score components
- +25RoleCEO
- +14Trade size$300k at market
- 0Share of holdings soldSold 9.3% of holdings
- 0ClusterNo other insider selling within 14 days
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
This signal so far: 1m -11.5%, 3m -38.1%, 6m -53.1%.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0001437749-25-036821, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Nov 28, 2025 | SOpen-market sale Common Stock | -200,000 | $1.50 | $300k | 1,946,755 | Dec 3, 2025 |
Related signals
Other insiders at Nuo Therapeutics, Inc. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 28Weak | AURXbuy Nuo Therapeutics, Inc. | David Emerson Jorden CEO/CFO | $9,539 8,773 shares | +0% | |
| 19Weak | AURXbuy Nuo Therapeutics, Inc. | Charles E Sheedy owner | $200k 133,333 shares | +1% | |
| 25Weak | AURXbuy Nuo Therapeutics, Inc. | Charles E Sheedy owner | $94k 125,000 shares | +1% | |
| 18Weak | AURXbuy Nuo Therapeutics, Inc. | Charles E Sheedy owner | $75k 100,000 shares | +1% | |
| 23Weak | AURXbuy Nuo Therapeutics, Inc. | Charles E Sheedy owner | $75k 150,000 shares | +1% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.